ASH 2017 | A RESPONSE to ruxolitinib: update on 4-year trial follow-up
Jean-Jacques Kiladjian
An exciting update on the 4-year follow-up of the RESPONSE Trial (NCT01243944) was given by Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. The RESPONSE trial compared the efficacy and safety of ruxolitinib vs. the best available therapy in patients with hydroxyurea-intolerant/resistant polycythemia vera (PV). Now, after conducting a 4-year follow-up on the study, Prof. Kiladijan discusses the results and the next steps.
Related videos
4:03
The earlier the better: detecting target genes in myeloproliferative neoplasms
Srdan Verstovsek
3:40
Genetic abnormalities for detecting patients at risk of AML
Srdan Verstovsek
1:34
The importance of quickly spotting the signs of AML
Srdan Verstovsek
4:19
Intervening on time: how hypomethylating agents can prevent transition to AML
Srdan Verstovsek
2:38
Heritability of MPNs
Valeria Santini
